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Background: Multidrug resistance in cancer is a major obstacle for clinical therapeutics, 
and is the reason for 90% of treatment failures. This study investigated the efficiency of novel 
multifunctional Fe3O4 magnetic nanoparticles (Fe3O4-MNP) combined with chemotherapy and 
hyperthermia for overcoming multidrug resistance in an in vivo model of leukemia.
Methods: Nude mice with tumor xenografts were randomly divided into a control group, and 
the treatment groups were allocated to receive daunorubicin, 5-bromotetrandrine (5-BrTet) and 
daunorubicin, Fe3O4-MNP, and Fe3O4-MNP coloaded with daunorubicin and 5-bromotetrandrine 
(Fe3O4-MNP-DNR-5-BrTet), with hyperthermia in an alternating magnetic field. We investigated 
tumor volume and pathology, as well as P-glycoprotein, Bcl-2, Bax, and caspase-3 protein expres-
sion to elucidate the effect of multimodal treatment on overcoming multidrug resistance.
Results: Fe3O4-MNP played a role in increasing tumor temperature during hyperthermia. Tumors 
became significantly smaller, and apoptosis of cells was observed in both the Fe3O4-MNP and 
Fe3O4-MNP-DNR-5-BrTet groups, especially in the Fe3O4-MNP-DNR-5-BrTet group, while 
tumor volumes in the other groups had increased after treatment for 12 days. Furthermore, 
Fe3O4-MNP-DNR-5-BrTet with hyperthermia noticeably decreased P-glycoprotein and Bcl-2 
expression, and markedly increased Bax and caspase-3 expression.
Conclusion: Fe3O4-MNP-DNR-5-BrTet with hyperthermia may be a potential approach for 
reversal of multidrug resistance in the treatment of leukemia.
Keywords: magnetic nanoparticles, daunorubicin, 5-bromotetrandrine, multidrug resistance, 
hyperthermia
Introduction
Multidrug resistance is the phenomenon of cross-resistance of mammalian cells to a 
number of anticancer agents following exposure to one type of drug, and is a major 
obstacle in cancer chemotherapy,1 especially in the treatment of leukemia. Although 
the mechanism of multidrug resistance is complex, it is mainly due to the activation of 
a family of energy-dependent drug efflux pumps, such as P-glycoprotein, which can 
transport drugs out of the cell.2 On the other hand, alternating expression of apoptosis-
related proteins, such as Bcl-2, caspase-3, and Bax, in multidrug-resistant cancer cells 
causes a lack of response to many front-line chemotherapeutic agents.3 Therefore, 
regulation of P-glycoprotein and apoptosis-related protein has attracted research interest 
in an effort to overcome multidrug resistance in the treatment of cancer.
In recent years, the need to overcome multidrug resistance using a rational approach 
has been emphasized.4 Chinese herbal medicine, nanoparticles, and hyperthermia have 
contributed a lot to this line of research.5–7 It is well known that hyperthermia adjuvant 
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to chemotherapy is playing an increasing role in the treatment 
of multidrug-resistant tumors in vivo, but temperature has 
been difficult to control.7 Fortunately, recent evidence in the 
literature suggests that magnetic nanoparticles can be used 
to improve the efficiency of hyperthermia and to regulate 
temperature at a stable level.8 The magnetic nanoparticles 
used for hyperthermia have a maximum temperature known 
as the Curie temperature, which is related to both magnetism 
and composition of the nanoparticles, but is not related to 
their concentration.9,10 Furthermore, the nanoparticles can 
be used to deliver anticancer drugs and reversal agents to 
improve the efficiency of treatment as well as to overcome 
drug resistance.11,12
Nowadays, some Chinese herbal medicines are con-
sidered to be able to reverse multidrug resistance in the 
treatment of cancer.5 Previous research has demonstrated 
that 5-bromotetrandrine (5-BrTet) can partly inhibit the 
function of P-glycoprotein, suppress antiapoptosis, and 
accumulate anticancer drugs in vivo and in vitro.5,13 Our 
own research has also demonstrated that Fe3O4 magnetic 
nanoparticles (MNP) enhance the efficiency of 5-BrTet and 
daunorubicin (DNR) in overcoming multidrug resistance in 
in vivo and in vitro models of cancer.14,15 Thus, we suspected 
that Fe3O4-MNP-DNR-5-BrTet with hyperthermia in an 
alternating magnetic field, as a multifunctional strategy, 
may have improved therapeutic efficiency. In the pres-
ent study, we investigated tumor volume, pathology, and 
expression of P-glycoprotein, Bcl-2, Bax, and caspase-3 
proteins to elucidate the effect of multimodal treatment 
in overcoming multidrug resistance after nude mice with 
tumor xenografts were treated with Fe3O4-MNP- DNR-5-
BrTet and hyperthermia.
Materials and methods
Main agents
Adriamycin was purchased from Hisun Pharmaceutical Co, 
Ltd (Zhejiang, China); DNR from Main Luck Pharmaceu-
ticals Inc (Shenzhen, China); 5-bromotetrandrin from Kang 
Hong Pharmaceuticals Inc (Chengdu, China); RPMI-1640 
from Gibco Chemical Co (Carlsbad, CA); trichloride ferric, 
ferrous sulfate, oleic acid, and ammonium hydroxide from 
Shanghai Hanguang Chemical Reagent Co, Ltd (Shanghai, 
China); Pluronic F-127 from Sigma-Aldrich (St Louis, MO); 
hematoxylin-eosin staining kit from Beyotime Institute 
of Biotechnology (Shanghai, China); fetal bovine serum 
from Hangzhou Sijiqing Biological Engineering Materials 
Co, Ltd (Hangzhou, China); and monoclonal antibodies to 
Bax, Bcl-2, caspase-3, and P-glycoprotein from Santa Cruz 
  Biotechnology Inc (Santa Cruz, CA).
Cell line and cell culture
A resistant human chronic myeloid leukemia cell line, K562/
A02, was received as a gift from the Institute of Hematology, 
Chinese Academy of Medical Sciences. It was established 
by stepwise selection with an increasing concentration of 
  adriamycin. The cells were maintained in RPMI-1640 medium 
with 10% fetal bovine serum, 100 µg/mL penicillin, and 
100 µg/mL streptomycin at 37°C in a humidified 5% CO2 
atmosphere. To maintain a multidrug-resistant phenotype, 
the cell line was cultured in a medium containing 1 g/mL 
adriamycin for at least 1 week before use.
Experimental animals
Athymic nude BALB/c mice (4 weeks of age, 16–20 g in 
weight) were purchased from the Shanghai National Center 
for Laboratory Animals. They were maintained in a specific 
pathogen-free facility on a 12-hour light/dark cycle and fed 
with sterile food. The indoor temperature was maintained 
at 22°C and humidity ranged from 40% to 50%. All animal 
experiments were performed in adherence with the Guide-
lines for the Care and Use of Laboratory Animals of the 
National Institutes of Health.
Preparation of Fe3O4-MNP  
and Fe3O4-MNP-DNR-5-BrTet
As described earlier, 26 g of ferric chloride hexahydrate, 
18 g of ferrous sulfate heptahydrate, 5 g of oleic acid, and 
50 mL of ammonium hydroxide (25%) were prepared for 
chemical reaction in nitrogen. The iron oxide nanoparticles 
were then prepared by coprecipitation of Fe3+ and Fe2+ with 
ammonium hydroxide. The prepared oleic acid-coated iron 
oxide nanoparticles were maintained at a high temperature 
and further modified with Pluronic F-127. Finally, the solu-
tion was gradually cooled to room temperature and extracted 
using a magnet, as previously described.17
After the aqueous dispersion of oleic acid-coated and 
Pluronic-modified iron oxide nanoparticles were   synthesized, 
the already prepared hydrophobic DNR and 5-Br-Tet were 
added dropwise into the aqueous dispersion by vigorous 
  magnetic force and stirring overnight to force the DNR and 
5-Br-Tet to enter in the oleic acid layer.16 The effective drug-
loading rate of DNR and 5-Br-Tet was approximately 8.25% 
(DNR:5-Br-Tet = 1:1 [w/w]), determined by   high-performance 
liquid chromatography with a fluorescence detector.17
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Multidrug-resistant leukemia xenograft 
model in nude mice
The nude mice were maintained in a specific pathogen-free 
facility for 7 days, and then injected with K562/A02 cells to 
establish a human multidrug-resistant leukemia xenograft 
model. Briefly, 1 × 107 K562/A02 cells suspended in 0.2 mL 
of RPMI-1640 medium were injected subcutaneously into 
the left posterior axilla of the nude mice. After the nude mice 
were injected with K562/A02 cells for about a week, a lump 
with skin-colored peplos was observed in the left posterior 
axilla of each mouse, which continued to grow larger until 
intervention, indicating that this lump was the multidrug-
resistant leukemia xenograft.
Treatment protocol
When the tumor size was 950 ± 150 mm3, 24 tumor-bearing nude 
mice were randomly divided into five groups. The treatment 
protocol included Group A, a negative control group in which 
each mouse was treated with 0.9% normal saline 0.2 mL; 
Group B, treated with DNR 1 mg/kg; Group C, treated with 
5-BrTet 1 mg/kg and DNR 1 mg/kg; Group D, treated with 
Fe3O4-MNP 22 mg/kg; and Group E, treated with Fe3O4-MNP-
DNR-5-BrTet 24 mg/kg, in which DNR was 1 mg/kg and 5-BrTet 
was 1 mg/kg. After administration of the study treatment, all 
mice were kept in an alternating magnetic field at a frequency 
of 219 kHz and a variable field strength of 10.5–310.1 kA/m 
for 40 minutes. Thereafter, the tumor inhibition rate in the mice 
was calculated and tumor volume growth characteristics were 
recorded for 12 days before sacrifice. The xenograft tumor was 
then harvested and processed for histopathologic analysis and 
determination of protein expression.
Tumor volume and inhibition rate
To evaluate the effect of the study treatment, two diameters 
of tumor were measured with digital calipers, and then tumor 
size was calculated using the following formulae:
V = 1/2 × a ×  b2
where v is tumor volume, a is the longest diameter, and b is 
the shortest diameter.
RTV = Vx/V0
where RTV is relative tumor volume, V0 represents the 
first day before treatment, and Vx represents the x day after 
treatment.
IR = 1 - RTV of experimental therapy
  group/RTV of control group
where IR is the inhibition rate.
Histopathologic examination of tumors
After the xenograft tumor was harvested, it was immediately 
fixed in 4% paraformaldehyde, dehydrated in a graded series 
of alcohol, and then embedded in paraffin. Slices 0.5 mm 
thick were cut and stained with hematoxylin and eosin for 
microscopic examination. All sections were observed in 
a blinded manner, and photographed using a 400× light 
microscope.
Western blot assays
Samples of tumor tissue weighing 0.1 g was collected 
from each mouse and homogenized for detection of 
P-  glycoprotein, Bcl-2, Bax, and caspase-3. Briefly, the   tissues 
were extracted with Triton X-100, and the proteins were 
separated using sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis and then electroblotted onto a polyvinylidene 
difluoride   membrane (BioRad Laboratories, Hercules, 
CA). The   membrane was blocked with buffer containing 
10%   fat-free dry milk. Thereafter, mouse anti-Bcl-2 anti-
body (1:400), mouse anti-Bax antibody (1:400), mouse 
  anti-  caspase-3   antibody (1:400), mouse anti-P-glycoprotein 
antibody (1:200), and anti-β-actin (1:400) were used as 
the primary antibody overnight, and then subsequently 
  incubated with a s  econdary horseradish peroxidase-
  conjugated   antirabbit   antibody (1:1000) for 1 hour at room 
temperature. The band was detected using an enhanced 
  chemiluminescence system.
Statistical analysis
All experimental data were expressed as the mean ± standard 
deviation and analyzed using SPSS software (version 13.0; 
SPSS Inc, Chicago, IL). A P value of ,0.05 was considered 
to be statistically significant.
Results
Characteristics of Fe3O4-MNP
An image of the oleic acid-Pluronic-modified Fe3O4-MNP is 
shown in Figure 1A. As observed by transmission electronic 
microscopy, the nanoparticles had a spherical shape and were 
dispersed uniformly. The size of the Fe3O4-MNP ranged from 
13.5 to 23.5 nm, and the mean size was 18.44 ± 1.84 nm 
(Figure 1B).
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Influence of extreme and moderate heat 
on tumors
After treatment with hyperthermia for different periods of 
time, the temperature change at the tumor site was deter-
mined and is shown in Table 1. It can be seen that the tumor 
temperature in the mice treated with Fe3O4-MNP increased 
to 41.71°C ± 1.52°C and in those treated with Fe3O4-MNP-
DNR-5-BrTet the temperature increased to 41.56°C ± 1.8°C 
after 20 minutes of hyperthermia. The tumor temperature was 
higher in these two groups than in the other groups, but there 
were no significant difference between them. Furthermore, no 
obvious change in temperature was observed in the mice not 
treated with Fe3O4-MNP throughout the study. Interestingly, 
except for the increased temperature at the tumor site, the 
mice treated with Fe3O4-MNP or Fe3O4-MNP-DNR-5-BrTet 
did not show any increase in temperature elsewhere. These 
results show that Fe3O4-MNP played an important role in 
the temperature changes at the tumor site in response to both 
extreme and moderate hyperthermia.
Volume and inhibitory rate  
in tumor tissue
All the mice were alive and no adverse reactions were 
observed during the 12 days of treatment. The tumor volume 
was smaller and smaller in a time-dependent manner in both 
the Fe3O4-MNP and Fe3O4-MNP-DNR-5-BrTet groups, espe-
cially in the Fe3O4-MNP-DNR-5-BrTet group. In contrast, 
the tumor volume in the other groups became increasingly 
large, and was markedly larger in the DNR and control groups 
than in the DNR and 5Br-Tet groups (Figure 2). Further, 
the RTV in the Fe3O4-MNP and Fe3O4-MNP-DNR-5-BrTet 
groups was much lower than in other groups (P , 0.05) at 
day 12 after treatment, as shown in Figure 3. Interestingly, 
from day 4 onwards, the RTV decreased markedly more 
rapidly in the Fe3O4-MNP-DNR-5-BrTet group than in the 
Fe3O4-MNP group (P , 0.05, Figure 3).
The tumor inhibition rate was higher in both the Fe3O4-
MNP and Fe3O4-MNP-DNR-5-BrTet groups than in the 
DNR group or in the group treated with DNR combined with 
5-BrTet (P , 0.05), and the change was particularly marked 
in the Fe3O4-MNP-DNR-5-BrTet group (Figure 5). The inhi-
bition rate was 75.92% ± 5.77% in the Fe3O4-MNP-DNR-5-
BrTet group and 65.31% ± 5.66% in the Fe3O4-MNP group, 
and higher than in the DNR (10.73% ± 4.58%) and DNR and 
5-BrTet groups (31.04% ± 8.22%; P , 0.05), suggesting that 
Fe3O4-MNP-DNR-5-BrTet with hyperthermia had the stron-
gest effect on tumor inhibition rate in a multidrug-resistant 
leukemia tumor model.
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Figure 1 (A) Image of oleic acid-Pluronic-modified iron oxide nanoparticles (Fe3O4-MNP) under transmission electronic microscopy. (B) Size distribution histogram of 
Fe3O4-MNP.
Abbreviation: Fe3O4-MNP, magnetic nanoparticles of Fe3O4.
Table 1 Temperature change of tumor site after treatment for different times (mean ± SD)
Group Temperature (°C)
0 minutes 10 minutes 20 minutes 30 minutes 40 minutes
A 30.85 ± 1.49 30.58 ± 1.62 30.38 ± 1.62 30.46 ± 1.96  29.71 ± 1.74
B 31.05 ± 1.96 30.71 ± 1.86 30.58 ± 1.71 30.75 ± 1.79 29.62 ± 1.63
C 31.02 ± 1.88 30.85 ± 1.49 30.67 ± 1.65 30.15 ± 1.53 29.67 ± 1.81
D 30.86 ± 1.96 35.73 ± 0.91 41.71 ± 1.52 42.91 ± 0.68 42.91 ± 0.63
E 30.88 ± 1.79 35.70 ± 1.07 41.56 ± 1.48 42.78 ± 0.46 42.78 ± 0.51
Notes: Group A, control; Group B, DNR; Group C, DNR and 5-BrTet; Group D, Fe3O4-MNP; Group E, Fe3O4-MNP-DNR-5-BrTet.
Abbreviations: DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; Fe3O4-MNP, magnetic nanoparticles of Fe3O4.
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Histopathologic examination of tumor 
tissue
Representative histopathological images showed the neoplas-
tic cells to have spherical heterogeneity with karyomegaly 
and dark blue nuclei, indicating more clear-edged mitotic 
figures (indicated by red arrows in Figure 5A and B). Few 
apoptotic cells were observed in the DNR-5-BrTet group, 
indicated by black arrows (Figure 5C). Notably, a reasonable 
quantity of apoptotic cells and an obvious apoptosis phe-
nomenon were observed in the Fe3O4-MNP-DNR-5-BrTet 
and Fe3O4-MNP groups; karyopyknosis and karyorrhexis 
could be observed in the apoptotic cells, especially in the 
Fe3O4-MNP-DNR-5-BrTet group. Moreover, some brown 
punctiforms in localized areas could be seen in the Fe3O4-
MNP and Fe3O4-MNP-DNR-5-BrTet groups, suggesting 
that Fe3O4-MNP can be targeted successfully to tumor tissue 
using additional hyperthermia.
P-glycoprotein, Bcl-2, Bax, and caspase-3 
protein expression
P-glycoprotein, Bcl-2, Bax and caspase-3 protein expression 
levels were detected by Western blotting, and are shown in 
Figure 6. There was no significant difference in relative inten-
sity between any of these proteins in the control and DNR 
groups. However, compared with the other groups, Bcl-2 
protein expression was markedly decreased and that of Bax 
and caspase-3 proteins was markedly increased in the Fe3O4-
MNP and Fe3O4-MNP-DNR-5-BrTet groups (P , 0.05). Also, 
the ratio of Bax/Bcl-2 was higher in the Fe3O4-MNP-DNR-
5-BrTet and Fe3O4-MNP groups than other groups, and there 
was a significant difference between the Fe3O4-MNP-DNR-
5-BrTet group and the other groups (P , 0.05). Furthermore, 
P-glycoprotein expression was significantly lower in the 
Fe3O4-MNP-DNR-5-BrTet group than in the other groups 
(P , 0.05). Interestingly, Fe3O4-MNP-DNR-5-BrTet was 
more effective than Fe3O4-MNP (P , 0.05).
Discussion
Chemotherapy is still the main method for the majority of 
tumor therapeutics. However, 90% of tumor chemotherapy 
failure due to multidrug resistance,18 the mechanism of 
which is complex. P-glycoprotein-mediated multidrug 
resistance is the major cause of failure of   chemotherapy. 
P-glycoprotein overexpressed in multidrug-resistant cancer 
Figure 2 Appearance of tumor body in tumor-bearing nude mice at day 12 after treatment.
Notes: (1) Controls, (2) DNR, (3) DNR and 5-BrTet, (4) Fe3O4-MNP, and (5) Fe3O4-MNP-DNR-5-BrTet.
Abbreviations: DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; Fe3O4-MNP, magnetic nanoparticles of Fe3O4.
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Figure 4 Tumor inhibition rate of mice at day 4 after treatment.
Abbreviations: DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; Fe3O4-MNP, 
magnetic nanoparticles of Fe3O4.
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Figure 3 Relative tumor volume of mice after treatment for 12 days.
Abbreviations: DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; Fe3O4-MNP, 
magnetic nanoparticles of Fe3O4.
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cells could induce the chemotherapy drugs to pump from 
the cells.4,5 Unfortunately, no P-glycoprotein inhibitors have 
been approved for clinical use after the failure of valspodar 
(PSC-833).19 On the other hand, apoptosis is an important 
metabolic step in regulating cell numbers and their growth, 
and multiple antiapoptotic signals have been shown to enable 
cancer cells to evade destruction by chemotherapeutic drugs. 
Proteins of the Bcl-2 family have either proapoptotic or anti-
apoptotic activity and regulate the mitochondrial pathway in 
apoptosis.20 However, Bax and Bcl-2 expression is abnormal 
in hematologic malignances, increasing by up to 21%.21 
Caspase-3 is the most characterized effector caspase, and its 
activation leads to the final stages of cell death.22 If Bcl-2 is 
highly expressed, the caspase-3 precursor cannot be activated 
and the apoptosis pathway is blocked,22 leading to disordered 
metabolism and tumor development.23 Therefore, there is an 
urgent global need to develop more effective strategies to 
overcome multidrug resistance.
In recent years, intensive research activity has been 
focused on certain Chinese herbal agents, which are safe and 
partly able to reverse multidrug resistance in cancer cells, 
and it has been found that 5-BrTet may be one such agent.5,25 
5-BrTet combined with chemotherapy would not increase the 
toxic effects or pharmacokinetic activity of a chemotherapeu-
tic agent.26 It is worth noting that considerable attention has 
been paid to nanoparticles and hyperthermia in developing 
rational and multifunctional compound therapeutics for 
cancer multidrug-resistant reversal.6,7
Figure 5 Histopathologic examinations of K562/A02 tumors at day 12 after treatment (hematoxylin-eosin staining, 400×). (A) control, (B) DNR, (C) DNR and 5-BrTet, 
(D) Fe3O4-MNP, and (E) Fe3O4-MNP-DNR-5-BrTet.
Abbreviations: DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; Fe3O4,-MNP, magnetic nanoparticles of Fe3O4.
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Many researchers have shown that chemotherapeutic 
agents loaded into nanoparticles have increased efficacy, 
solubility, and low toxicity, and that the drug is protected 
against chemical and biological degradation.26–28 Because 
of these advantages, nanoparticles can be considered to 
be potential chemotherapeutic drug carriers for treating 
multidrug-resistant cancers. Interestingly, one study of nano-
particles loaded with a chemotherapeutic agent has shown 
reversal of multidrug resistance.6 At present, Fe3O4 is one of 
the most commonly used nanoparticle materials, with low 
toxicity, magnetic properties, and minimal impact on body 
metabolism.6,26,29 In order to make the magnetic nanoparticles 
accumulate locally at the tumor site, an external alternating 
magnetic field is usually required, as well as magnetic nano-
particles with additional hyperthermia.29
Hyperthermia is an old but nowadays rapidly developing 
method of treating cancer, whereby a temperature of 40°C–45°C 
is considered optimal for hyperthermia.30   However, magnetic 
nanoparticles interact with each other in the magnetic field 
and this interaction inevitably influences the efficiency of 
  hyperthermia.31 Milleron and Bratton32 demonstrated that 
hyperthermia could increase local drug concentration and cause 
apoptosis of cancer cells via the mitochondrial pathway. Another 
study33 reported that heat generated in this way was more homo-
geneous than heat generated using a macroscopic implant, so it 
is rational to target tumor   tissue using locally concentrated mag-
netic   nanoparticles. There is evidence in the literature that 
hyperthermia can cause local drug accumulation in tumor 
tissue, leading to apoptosis of cancer cells and a change in 
the microenvironment of the cancer cell, which in turn affects 
anticancer immunity in the body.34,35 Sonvico et al36 treated 
tumor-bearing mice with a magnetic nanomedicine mediated 
hyperthermia, and 12 days after treatment, the nanomedicine 
in local tumor decreased to 50% of the dose of the drug at the 
beginning of the treatment. In our study, with the addition of 
hyperthermia, tumor temperature was higher in mice treated 
with Fe3O4-MNP or Fe3O4-MNP-DNR-5-BrTet than in the other 
groups, and was maintained at a stable level, with no change in 
temperature at other body sites in the mice. These results are 
in agreement with the histopathologic observation of an obvi-
ous apoptosis phenomenon in cancer cells in the mice treated 
with Fe3O4-MNP or Fe3O4-MNP-DNR-5-BrTet; the inhibition 
rate in the Fe3O4-MNP-DNR-5-BrTet group was much higher 
than in the other groups after 4 days of treatment. Furthermore, 
P-glycoprotein and Bcl-2 expression in the Fe3O4-MNP-DNR-
5-BrTet group was markedly decreased, that of caspase-3 was 
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remarkably increased, and the proportion of Bax and Bcl-2 was 
significantly increased. According to our previous research, 
Fe3O4-MNP-DNR-5-BrTet can release a drug in a sustained 
manner for longer than 12 days,34 so Fe3O4-MNP-DNR-5-
BrTet with hyperthermia in vivo could efficiently overcome 
tumor multidrug resistance for 12 days by releasing DNR 
and 5-Br-Tet from Fe3O4-MNP. In the present study, tumor 
volume continued to decrease over 12 days, and nanoparticles 
were observed in the tumor tissue on histopathologic examina-
tion after a single treatment with Fe3O4-MNP-DNR-5-BrTet. 
Meanwhile, we found that the same dose of DNR with 5-BrTet 
only decreased the speed of tumor growth and had much less 
effect on overcoming multidrug resistance than did Fe3O4-
MNP-DNR-5-BrTet. Furthermore, compared with previous 
research, the addition of hyperthermia not only caused Fe3O4-
MNP to be a more effective treatment, but also improved the 
efficiency of Fe3O4-MNP-DNR-5-BrTet to a greater extent than 
did daily administration without hyperthermia.15 Notably, all 
the nude mice remained alive, and no adverse reactions were 
observed after administration of Fe3O4-MNP-DNR-5-BrTet 
with hyperthermia. Thus, Fe3O4-MNP-DNR-5-BrTet with 
hyperthermia has decisive advantages in the treatment of local 
malignant tumor tissue.
Conclusion
In conclusion, Fe3O4-MNP-DNR-5-BrTet with addition of 
hyperthermia as a multifunctional strategy could efficiently 
overcome multidrug-resistant leukemia by downregulating 
P-glycoprotein expression and upregulating the ratio of Bax/
Bcl-2. These findings demonstrate that Fe3O4-MNP-DNR-
5-BrTet with hyperthermia may be a potential approach to 
reverse multidrug-resistant leukemia.
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